跳至主要内容
临床试验/NL-OMON54757
NL-OMON54757招募中2 期

Imaging tumor angiogenesis using 18F-Fluciclatide PET/CT in patients with colorectal and pancreatic cancer. - 18F-Fluciclatide tumor imaging.

eids Universitair Medisch Centrum0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Biopsy proven primary colorectal adenocarcinoma or suspected pancreatic ductal
  • adenocarcinoma, as agreed on by multidisciplinary team;
  • No prior chemo(radio)therapy in rectal cancer patients.
  • Patients treated in the LUMC.
  • Before patient registration, written informed consent must be given according
  • to ICH/GCP, and national/local regulations.

排除标准

  • Contraindication for PET (pregnancy, breast-feeding and severe claustrophobia);
  • Impaired renal function (creatinine clearance < 60 mL/min according to the
  • Cockcroft-Gault equation or ureum < 2x ULN (Upper limit of normal);
  • Impaired liver function (ALAT, ASAT > 3 ULN or total bilirubin >2x ULN);
  • Known allergy to pABA (p-aminobenzoate sodium salt);
  • Presence of any psychological, familial, sociological or geographical condition
  • potentially hampering compliance with the study protocol and follow-up
  • Inability to tolerate lying supine for the duration of a PET/CT examination

研究者

相似试验